Thursday, the FDA approved AstraZeneca Plc’s (NASDAQ:AZN) Tagrisso (osimertinib) for adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy (CRT).
Tagrisso is indicated for patients with exon 19 deletions or exon 21 (L858R) mutations.
Also Read: Latest Trial Setback For AstraZeneca’s Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients.
Tagrisso is AstraZeneca’s top-selling cancer drug, and in the second quarter of 2024, it generated around $1.6 billion in sales.
The
